PCM
BBIO icon

Prelude Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Prelude Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,807
Closed -$1.03M – 1254
2026
Q1 		$1.03M Sell
13,807
-10,430
-43% -$756K 0.08% 301
2025
Q4 		$1.85M Sell
24,237
-15,612
-39% -$1.02M 0.14% 164
2025
Q3 		$2.07M Sell
39,849
-10,974
-22% -$535K 0.16% 155
2025
Q2 		$2.19M Sell
50,823
-18
-0% -$655 0.21% 123
2025
Q1 		$1.76M Sell
50,841
-17,859
-26% -$602K 0.13% 171
2024
Q4 		$1.89M Buy
68,700
+7,550
+12% +$195K 0.12% 199
2024
Q3 		$1.56M Buy
61,150
+37,839
+162% +$993K 0.09% 275
2024
Q2 		$590K Buy
23,311
+11,797
+102% +$323K 0.04% 470
2024
Q1 		$356K Sell
11,514
-3,740
-25% -$127K 0.02% 808
2023
Q4 		$616K Buy
15,254
+40
+0.3% +$1.2K 0.04% 432
2023
Q3 		$401K Sell
15,214
-3,827
-20% -$109K 0.03% 545
2023
Q2 		$328K Buy
19,041
+3,764
+25% +$56.6K 0.02% 602
2023
Q1 		$253K Sell
15,277
-8,124
-35% -$94.7K 0.02% 732
2022
Q4 		$178K Buy
+23,401
New +$224K 0.01% 997

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Prelude Capital Management's BBIO Position: Q2 2026 in Review

Prelude Capital Management sold out of BridgeBio Pharma (BBIO) in Q2 2026, closing a stake of 13,807 shares — an estimated $1.03M sold.

Prelude Capital Management first reported a position in BBIO in Q4 2022 and held it in 14 quarters. The position peaked at $2.19M in Q2 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Prelude Capital Management reported no remaining BridgeBio Pharma position as of Q2 2026 after selling out during the quarter.
  • Prelude Capital Management sold 13,807 BridgeBio Pharma shares in Q2 2026, an estimated $1.03M.
  • Prelude Capital Management first reported a position in BridgeBio Pharma in Q4 2022 and held it in 14 quarters.
  • Prelude Capital Management's BridgeBio Pharma position peaked at $2.19M in Q2 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.